Patient Outcomes Summary:
Cellular Therapy Treatment & its Effects on COPD

Ongoing Results Case Study for COPD Patients Treated by the Lung Institute | Jack Coleman Jr., M.D.

Today more than 600 million people suffer from chronic obstructive pulmonary disease (COPD) worldwide. Although there is no cure for COPD, recent advancements in cellular therapy have made it possible not only to relieve symptoms but to promote healing within the lungs themselves.

After testing 349 patients, the Lung Institute has discovered that within three months of treatment, 84.5 percent of patients found their quality of life had improved. Among other promising statistics, this discovery could change lives significantly.

Introduction by the Lung Institute:

The Problem with Chronic Pulmonary Diseases

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder that occurs as a result of prolonged cigarette smoking, second-hand smoke and polluted air or working conditions. COPD is the most prevalent form of chronic lung disease. The physiological symptoms of COPD include shortness of breath (dyspnea), cough and sputum production, exercise intolerance and reduced Quality of Life (QOL). These signs and symptoms are brought about by chronic inflammation of the airways, which restricts breathing. When fibrotic tissues contract, the lumen is narrowed, compromising lung function. As histological studies confirm, airway fibrosis and luminal narrowing are major features that lead to airflow limitation in COPD1-3.

Today, COPD is a serious global health issue, with a prevalence of 9 percent to 10 percent of adults aged 40 and older4. And the prevalence of the disease is only expected to rise. Currently, COPD accounts for 27 percent of tobacco-related deaths and is anticipated to become the fourth leading cause of death worldwide by 20305. Today, COPD affects approximately 600 million individuals–roughly 5 percent of the world’s population6. Despite modern medicine and technological advancements, there is no known cure for COPD.

The difficulty in treating COPD and other lung diseases rests in the trouble of stimulating alveolar wall formation15. Until recently treatment has been limited by two things: a lack of understanding of the pathophysiology of these disease processes on a molecular level and a lack of pharmaceutical development that would affect these molecular mechanisms. This results in treatment focused primarily on addressing the symptoms of the disease rather than healing or slowing the progression itself.

The result is there are few options available outside of bronchodilators and corticosteroids15. Although lung transplants are performed as an alternative option, there is currently a severe shortage of donor lungs, leaving many patients to die on waiting lists prior to transplantation. Lung transplantation is also a very invasive form of treatment, commonly offering poor results, a poor quality of life with a 5-year mortality rate of approximately 50 percent, and a litany of health problems associated with lifelong immunosuppression13.

However, it has been shown that undifferentiated multipotent endogenous tissue cells (cells that have been identified in nearly all tissues) may contribute to tissue maintenance and repair due to their inherent anti-inflammatory properties. Human mesenchymal stromal cells have been shown to produce large quantities of bioactive factors including cytokines and various growth factors which provide molecular cueing for regenerative pathways. This affects the status of responding cells intrinsic in the tissue18. These bioactive factors have the ability to influence multiple immune effector functions including cell development, maturation, and alloreactive T-cell responses19. Although research on the use of autologous cells (both hematopoietic and mesenchymal) in regenerative cellular therapy is still in the early stages of implementation, it has shown substantive progress in treating patients with few if any adverse effects.

Treatment Overview

Summary of Process

The Lung Institute (LI) provides treatment by harvesting autologous cells (hematopoietic cells and mesenchymal stromal cells) by withdrawing peripheral blood. These harvested cells are isolated and concentrated, and along with platelet-rich plasma, are then reintroduced into the body through the pulmonary vasculature (vessels of the lungs) where cells are trapped in the microcirculation (the “pulmonary trap”).


Individuals diagnosed with COPD were tracked by the Lung Institute to measure the effects of treatment both their pulmonary function as well as their Quality of Life.

Pulmonary Function Test (PFT)

All PFTs were performed according to national practice guideline standards for repeatability and acceptability8-10. On PFTs, pre-treatment data was collected through on-site testing or through previous medical examinations by the patient’s primary physician (if done within two weeks). The test was then repeated by their primary physician 6 months after treatment.*

* Due to the voluntary nature of patients being requested to submit their independent exam information, a sample size of 53 patients has been reflected within the PFT data.

Quality of Life Survey (QLS) & Quality Improvement Score (QIS)

Patients with progressive COPD typically will experience a steady decrease in their Quality of Life. Given this development, a patient’s Quality of Life score is frequently used to define additional therapeutic effects, with regulatory authorities frequently encouraging their use as primary or secondary outcomes17. As of 2013 the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has updated their stance on quality of life assessment, recommending that the Clinical COPD Questionnaire be used as an alternative to the COPD Assessment Test (CAT)20.

On quality of life testing, data was collected through the implementation of the Clinical COPD Questionnaire (CCQ) based survey17. The survey measured the patient’s self-assessed quality of life on a 0-6 scale, with adverse Quality of Life correlated in ascending numerical order. It was implemented in three stages: pre-treatment, 3-months post-treatment, and 6-months post-treatment. The survey measured two distinct outcomes: the QLS score, which measured the patient’s self-assessed quality of life score. And the QIS, a percentage-based measurement determining the proportion of patients within the sample that experienced QLS score improvements.


Cellular Therapy Patient DemographicsOver the duration of six months, the results of 349 patients treated for COPD through cellular based therapies were tracked by the Lung Institute in order to measure changes in pulmonary function and any improvement in Quality of Life.

Of the 349 patients treated by the Lung Institute, 213 were male (61 percent) while 136 were female (36 percent). Ages of those treated range from 40-92 years old with an average age of 71.



Cellular Therapy Quality Improvement ScoreOver the course of the study, patients saw an average increase of 33.5 percent to their Quality of Life (QLS) score within three months of treatment. While in the QIS, 84.5 percent of all patients found that their Quality of Life score had improved within three months of treatment (figure 1.2).

Within the PFT results, 49.1 percent of patients tested saw an increase of over 10 percent to their original pulmonary function, with an average increase of 12 percent. During the three- to six-month period after treatment, patients naturally saw a small decline in their progress, with QLS scores dropping from 33.5 percent to 32 percent, and the QIS from 84.5 percent to 81.7 percent.

Although it is reasonable to assume that a placebo effect may be evident in the more subjective and qualitative metrics such as the QLS and QIS scores—which may serve to affect perceptions of pain, fatigue and well-being—objective measurements such as the pulmonary function will not be affected by this phenomenon. Therefore, it is evident that cellular therapy can have a direct effect on the physiological lung function of a patient21.

wp_2016-09_fev1Fletcher and Peto’s work shows that patient survival rate can be improved through appropriate or positive intervention14 (figure 1.4). Though quitting smoking will mitigate the harmful effects of cigarette smoke, unlike cellular therapy, no evidence has shown that quitting smoking alone can increase pulmonary function. It remains to be seen if better quality of life will translate to longevity, but if one examines what factors allow for improved quality of life such as improvement in oxygen use, exercise tolerance, medication use, visits to the hospital and reduction in disease flare-ups then one can see that quality of life improves in association with clinical improvement.


Currently, the most utilized options for treating COPD are bronchodilator inhalers with or without corticosteroids and lung transplant– each has downsides. Inhalers are often used incorrectly11, are expensive over time, and can only provide temporary relief of symptoms. Corticosteroids, though useful, have risk of serious adverse side effects such as infections, blood sugar imbalance, weight gain to name a few16. Lung transplants are expensive, have an adverse impact on quality of life and have a high probability of rejection by the body; the treatment of which creates a new set of problems for patients. In contrast, initial studies of cells treatments show efficacy, lack of adverse side effects and may be used in conjunction with other treatments.


Through the data collected by the Lung Institute, development of methodologies for this form of treatment is taking place with other entities in the medical community quickly following suit. In a recent study of regenerative cellular therapy done by the University of Utah, patients exhibited improvement in PFTs and oxygen requirement compared to the control group with no acute adverse events12. Through the infusion of cells derived from the patient’s own body, cellular therapy minimizes the chance of rejection to the highest degree, promotes healing and can improve the patient’s pulmonary function and quality of life with no adverse side effects.

Although more studies using a greater number of patients is needed to further examine objective parameters such as PFTs, exercise tests, oxygen, medication use and hospital visits, larger sample sizes will also help determine if one protocol is more beneficial than others. With deeper research, utilizing economic analysis along with longer-term follow-up will answer questions on patient selection, the benefits of repeated treatments, and a possible reduction in healthcare costs for COPD treatment.

The field of Cellular Therapy and Regenerative Medicine is rapidly advancing and providing effective treatments for diseases in many areas of medicine. The Lung Institutes strives to provide the latest in safe, effective therapy for chronic lung disease and maintain a leadership role in the clinical application of these technologies.

Although cellular therapy has shown substantive progress in treating chronic lung disease, it is not a cure. Cellular therapy cannot serve to grow new lung tissue, but can only work to stop or slow the progression of the disease itself. As with any form of treatment, the intended benefits of cellular therapy are not universal, and not every patient will respond equally to treatment. In the case of those who see progress in their condition, it may be gradually eroded by the degenerative nature of lung disease, ultimately requiring additional boosters to maintain the same effects.

In a landscape of scarce options and rising costs, the Lung Institute believes that cellular therapy is the future of treatment for those suffering from COPD and other lung diseases. Although data is limited at this stage, we are proud to champion this form of treatment while sharing our findings.

In accordance with the most up-to-date draft guidelines and exemptions set forth by the Food and Drug Administration on the use of human cells, tissues, and cellular and tissue-based products, the Lung Institute has continued to practice safe and effective treatment within full compliance of current industry mandates and regulations.

  1. Kuwano K, Bosken C, Pare P, Bai T, Wiggs B, Hogg J. Small airways dimensions in asthma and chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1220-25
  2. Hogg J, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53.
  3. Niewoehner D. Structure-function relationships: the pathophysiology of airflow obstruction. In: Stockley R, Rnnard S. Rabe K, Celli B, eds. Chronic Obstructive Pulmonary Disease. Hoboken, NJ: Blackwell, 2007: 3-19.
  4. Halbert R, Natoli J. Gano A, Badamgarav E, Buist A, Mannino D. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 423-32.
  5. Fernando J Martinez, James F Donohue, Stephen I Rennard. The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 2011; 378: 1027-37.
  6. Michelle J. Hansen, Rosa C. Gualano, Steve Bozinovski, Ross Vlahos, Gary P. Anderson. Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). Pharmacology & Therapy 2006; 109: 162-172.
  7. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of Chronic Obstructive Pulmonary Disease (COPD). London: European Medicines Agency, 2010.
  8. Wanger J, Clausen JL, Coastes A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26(3): 511-22.
  9. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26(2):319-38. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166(4):518-624.
  10. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26 (4): 720-35.
  11. Int J Chron Obstruct Pulmon Dis. 2008 Sep; 3(3): 371–384.
  12. J. Tuma, F. Silva, A.A. Winters, C. Bartlett, A.N. Patel. Maison de Sante. Lima, Peru; University of Utah, Salt Lake City, UT.
  13. Viranuj Sueblinvong, MD and Daniel J. Weiss, M.D., PHD. Cells and Cell Therapy Approaches in Lung Biology and Diseases. 2010.
  14. Tantucci C, Modina D. Lung function decline in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2012; 7:95-99. doi:10.2147/COPD.S27480.
  15. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nas Med 1997; 3: 675-77.
  16. Samy Suissa, Valerie Patenaude, Francesco Lapi, Pierre Ernst. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
  17. Clinical COPD Questionnaire. Accessed October 28, 2015.
  18. Tracey L. Bonfield, Arnold I. Caplan. Adult Mesenchymal Cells: An Innovative Therapeutic for Lung Diseases. Discovery Medicine. April 2010; 9(47): 337-345.
  19. Giselle Chamberlain, James Fox, Brian Ashton, Jim Middleton. Mesenchymal Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing. Cells. 2007; 25:2739-2749.
  20. Samantha S.C. Kon, M.D., Jane L. Canavan, Ph.D., Claire M. Nolan, B.Sc., Sarah E. Jones, M.Sc, Amy L. Clark, B.Sc., Michel I. Polkey, M.D., Ph.D., and William D.-C. Man, M.D., Ph.D. The Clinical Chronic Obstructive Pulmonary Disease Questionnaire: Cut Point for GOLD 2013 Classification. Am J Respir Crit Care Med. 2014 Jan 15; 189(2): 227-228.
  21. Michael E. Wechsler, M.D., John M. Kelley, Ph.D., Ingrid O.E. Boyd, M.P.H., Stefanie Dutile, B.S., Gautham Marigowda, M.B., Irving Kirsch, Ph.D., Elliot Israel, M.D., and Ted J. Kaptchuk. Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in Asthma. N Engl J Med 2011; 365:119-126.

Are you a candidate? Call 888-745-6697 to find out.

For millions of people suffering from COPD, a natural decline in pulmonary health is a harsh reality. Based on these results, cellular therapy could be the answer they’ve been looking for.

*For more information, go to

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.